In TNBC, loss-of-function mutations or downregulation of ARID1A disturb cell cycle regulation and DNA repair, increase EMT, and activate the PI3K/AKT pathway, forcing aggressive tumor proliferation and resistance to treatments. The gene discussed is AKT1; the disease is neoplasm.